Purpose of this Study
We are doing this study to find out if an investigational drug called RMC-9805 (the study drug) is a safe and effective option for treating KRAS G12D mutated cancer. We are also trying to figure out what dose of the study drug works best for most people.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Have solid tumor(s) that are locally advanced or metastatic
- Have a documented KRAS G12D mutation
- Have worsened following standard therapy
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
[RMC-9805-001] Phase 1/1b, multicenter, open-label, study of RMC-9805 in participants with advanced KRASG12D-mutant solid tumors
Principal Investigator
John
Strickler
Protocol Number
PRO00114818
NCT ID
NCT06040541
Phase
I
Enrollment Status
Open to Enrollment